Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $124.8 million.

  • BeOne Medicines' Consolidated Net Income rose 20287.68% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 10796.67%. This contributed to the annual value of -$644.8 million for FY2024, which is 2687.08% up from last year.
  • As of Q3 2025, BeOne Medicines' Consolidated Net Income stood at $124.8 million, which was up 20287.68% from $94.3 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Consolidated Net Income ranged from a high of $215.4 million in Q3 2023 and a low of -$590.7 million during Q4 2021
  • In the last 5 years, BeOne Medicines' Consolidated Net Income had a median value of -$348.4 million in 2023 and averaged -$250.1 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 75448.23% in 2022, then surged by 20287.68% in 2025.
  • BeOne Medicines' Consolidated Net Income (Quarter) stood at -$590.7 million in 2021, then increased by 24.61% to -$445.3 million in 2022, then increased by 17.47% to -$367.6 million in 2023, then surged by 58.68% to -$151.9 million in 2024, then surged by 182.2% to $124.8 million in 2025.
  • Its last three reported values are $124.8 million in Q3 2025, $94.3 million for Q2 2025, and $1.3 million during Q1 2025.